Ally Bridge Group
Global healthcare investment management firm focused on life-science innovation. Founded in 2013 with offices in New York and Hong Kong, the firm invests across private and public capital structures and combines scientific and clinical research evaluation with M&A and capital markets execution to support portfolio company development and cross-border commercialization. The firm is active in buyouts, take-private transactions and public listing advisory, including cross-border listings and relistings between the U.S., Hong Kong and mainland China.
Industries
Finance
Financial Services
Health Care
Venture Capital
Nr. of Employees
small (1-50)
Ally Bridge Group
Expertise Areas
- Healthcare investment management
- Private equity and buyout transactions
- Public equity and IPO advisory
- Cross-border market access (U.S.-China-Europe)
Key Technologies
- Next-generation sequencing (NGS) and genomics
- Single-cell and multi-omics analysis
- AI/ML-driven drug discovery
- Surgical robotics platforms